Company: Sun Pharmaceutical Industries Ltd. Category: Result Analysis


NULL
May 29, 2019, 10:45 a.m.
Publisher: moneycontrol.com

NULL
Feb. 13, 2019, 11:04 a.m.
Publisher: moneycontrol.com

Global brokerage firms have a target price in the range of Rs 535-560 on Sun Pharma which translates into an upside of 22-28 percent return in the next 12 months.
Feb. 13, 2019, 10:32 a.m.
Publisher: moneycontrol.com

Emkay and Motilal Oswal see 17 percent year-on-year growth in bottomline while Prabhudas Lilladher expects profit to grow 137 percent and ICICI Securities expects 178 percent
Feb. 12, 2019, 11:06 a.m.
Publisher: moneycontrol.com


Net Sales are expected to increase by 14.4 percent Y-o-Y (up 9.7 percent Q-o-Q) to Rs. 7,609 crore, according to ICICI Direct.
Jan. 11, 2019, 6:09 p.m.
Publisher: moneycontrol.com

Net Revenues for the quarter increased by 4.3% YoY to Rs 69.4 bn, below our expectation of Rs 75.8 bn.
Nov. 14, 2018, 10:54 a.m.

Sun Pharmaceutical Industries (SUNP) has delivered a below par performance in Q2FY19.
Nov. 14, 2018, 10:50 a.m.
Publisher: trade.rsec.co.in

Operational performance shows improvement, with EBITDA rising 11 percent.
Nov. 13, 2018, 4:08 p.m.
Publisher: moneycontrol.com

SUNP’s net sales, adj. EBITDA and adj. PAT declined by 4%, 5% and 1% QoQ respectively due to declining sales in negative development in key geographies.
Nov. 13, 2018, 11:20 a.m.
Publisher: plindia.com

Brokerages expect profit to be around Rs 950-1,087 crore.
Nov. 13, 2018, 9:30 a.m.
Publisher: moneycontrol.com

-->